Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

NCT06583837

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations: Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China

View Trial Details

Active, Not Recruiting

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

NCT03589222

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Hospital Germans Trials i Pujol Badalona, Spain

Hospital Clinic de Barcelona Barcelona, Spain

Hospital ICO de Girona Girona, Spain

Hospital ICO de L'hospitalet L'Hospitalet de Llobregat, Spain

View all 15 locations

View Trial Details

Active, Not Recruiting

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

NCT04764942

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Active, Not Recruiting

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

NCT04624633

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +17 more
Locations: Dana Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

NCT05650723

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +13 more
Locations: Weill Cornell Medicine/NewYork-Presberteryian Hospital New York, United States

View Trial Details

Active, Not Recruiting

A Study of BN104 in the Treatment of Acute Leukemia

NCT06052813

Conditions: ALL, Adult, AML, Adult, Acute Leukaemia, +17 more
Locations: The First Affiliated Hospital of Soochow University Suzhou, China

View Trial Details

Active, Not Recruiting

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

NCT06524375

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations: Highlands Oncology Group Springdale, Arkansas, United States

Rocky Mountain Cancer Centers (Aurora) - USOR Aurora, Colorado, United States

Cancer Specialists of North Florida Jacksonville, Florida, United States

Fort Wayne Medical Oncology and Hematology, Inc Fort Wayne, Indiana, United States

View all 20 locations

View Trial Details

Active, Not Recruiting

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

NCT00378105

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Massachusetts General Hospital Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring

NCT05587972

Conditions: Blood Protein Disorders, Breast Cancer, Breast Diseases, +29 more
Locations: Cleveland Clinic Cleveland, Ohio, United States

View Trial Details

Active, Not Recruiting

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

NCT05577000

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: University of California, San Francisco San Francisco, California, United States

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions